|Awarded On||February 15, 2023|
|Title||Development and evaluation of lanosterol synthase inhibitors in preclinical GBM models|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Samuel McBrayer|
|Cancer Sites||Brain and Other Nervous System|
*Pending contract negotiation
Glioblastoma (GBM) is the most common form of cancer that forms in the brain and one of the most difficult cancers to treat. No new drugs have been approved for GBM therapy in more than a decade. To identify new drugs, our colleagues tested thousands of unique chemicals. Of the chemicals that showed promising activity against GBM cells, we discovered that one chemical, 5J12, blocks a protein called lanosterol synthase (LSS) that is involved in making a key component of human cells: cholesterol. Others have shown that reducing cholesterol levels in GBM cells can kill them effectively. However, there are currently no safe and effective ways to reduce cholesterol in GBM tumors. We showed that 5...